Compare Ascendis Pharma A/S (ASND) vs Newmont Corporation (NEM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Newmont Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Newmont Corporation trades at $94.7 (market cap $101.73B). The key difference: Newmont Corporation is far larger — about 5.7× Ascendis Pharma A/S's market cap, and Newmont Corporation pays a 1.09% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | NEM | |
|---|---|---|
Market Cap | $17.74B | $101.73B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $131.95 |
52-Week Low | $163.32 | $57.35 |
Enterprise Value | $18.11B | $98.48B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Newmont Corporation (NEM) trades at $95.29, up 0.51% with bearish technical signals but strong fundamentals. The gold miner reported record Q1 2026 earnings of $2.90 EPS, beating estimates by 40%, with revenue growth accelerating to 46% year-over-year. Analyst consensus remains strongly bullish with 75% buy ratings and a $141 price target representing 48% upside. Cash flow generation reached $3.1 billion in Q1, supporting dividend payments and debt reduction.
Despite gold price volatility creating near-term pressure, Newmont's operational excellence and margin expansion support long-term value. The stock trades at attractive valuations (P/E 12.4x) with 34% net margins, though exposure to commodity cycles and recent technical weakness require careful risk management. The upcoming Q2 earnings on July 23 will be critical for confirming the growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
